Skip to content

Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans

Evaluation of the Bioavailability and Production of Short Chain Fatty Acids in the Colon. A Stable Isotope Study in Healthy Humans.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01757379
Enrollment
12
Registered
2012-12-28
Start date
2011-04-30
Completion date
Unknown
Last updated
2015-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short Chain Fatty Acids Bioavailability

Keywords

Short chain fatty acids, Acetate, Propionate, Butyrate, Bioavailability

Brief summary

The purpose of the study is to evaluate the bioavailability of acetate, propionate and butyrate in healthy humans using a stable isotope technology. In addition the level of acetate, propionate and butyrate production from inulin will be determined using the principle of isotope dilution.

Interventions

DIETARY_SUPPLEMENT13C-labeled Acetate

400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)

DIETARY_SUPPLEMENT13C-labeled propionate

340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)

DIETARY_SUPPLEMENT13C-labeled butyrate

990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)

DIETARY_SUPPLEMENTInulin

15 g of inulin dissolved in 200 ml of water

Sponsors

KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * Regular dietary pattern (3 meals/day) * Age: 18-65y * BMI: 18,5-27 kg/m2

Exclusion criteria

* Intake of antibiotics 1 month prior to the study * Abdominal surgery in the past, with the exception of appendectomy * Intake of medication influencing the gastro-intestinal system 14 days prior to the study * In treatment at a dietician * Intake of pre- and/or probiotics * Exposure to radioactivity 1 year prior to the study * Serious chronic disease of the gastrointestinal tract * Use of medication that affects the gastro-intestinal tract during the last 2 weeks prior to the study * Pregnancy, pregnancy desire or lactation * Blood donation during the last 3 months prior to the study * Diabetes (type 1 or 2) * Aberrant hemoglobin level (Hb) in blood. Normal between 14.0 and 18.0 g/dL for men and between 12.0 and 16.0 g/dL for women

Design outcomes

Primary

MeasureTime frameDescription
Concentrations of the short chain fatty acids (acetate, propionate and butyrate) in plasma and urine samples12 hours each test day and 4 test days/volunteerParticipants performed each 4 test days and they were followed each test day for 12 hours, with sample collections at regular time points. Blood samples were collected every hour during the first 4 hours and afterwards every 20 minutes during 8 hours. Urine samples were collected during 24h in different fractions: 0-4h, 4-8h, 8-12h, 12-24h.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026